Comparison of baseline characteristics between a contemporary >real world< STEMI cohort and the PLATO and TRITON trial populations
| Autor: | Martin Hellmich, Hans-Wilhelm Hoepp, Hannes Reuter, Christian Wegmann, Roman Pfister, Anne Markhof, Steffen Scholz |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
education.field_of_study Prasugrel business.industry Population medicine.disease law.invention Randomized controlled trial law Internal medicine Cohort Conventional PCI Inclusion and exclusion criteria Cardiology medicine cardiovascular diseases Myocardial infarction Cardiology and Cardiovascular Medicine education business Killip class medicine.drug |
| Zdroj: | European Heart Journal. 34:P2240-P2240 |
| ISSN: | 1522-9645 0195-668X |
| Popis: | Purpose: Broader non-trial populations might differ from populations of randomized controlled trials (RCT) due to selected inclusion and exclusion criteria. Knowledge of these potential differences is crucial to generalize from trial results Methods: We used prospective registry data of 1289 patients of one interventional center participating in a metropolitan network established for obligatory treatment of acute ST-elevation myocardial infarction (STEMI) by primary PCI assessed from November 2006 to December 2011 to compare 17 characteristics of demography, co-morbidity and disease severity with published data of the STEMI subpopulations of the "Platelet Inhibition and Patient Outcomes" (PLATO) and the "Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel" (TRITON) trial. Results: Compared to PLATO our population showed significant differences with higher age, higher prevalence of hyperlipidaemia, renal dysfunction, Killip class 3-4, history of PCI, CABG and heart failure, a higher heart rate, lower diastolic blood pressure, and a lower prevalence of smokers and left-bundle branch block. Compared to TRITON our population showed significant differences with higher age, higher prevalence of women, hypertension, hyperlipidaemia, renal dysfunction, history of CABG and myocardial infarction and a lower prevalence of smokers. Conclusions: Patients enrolled in recent RCTs of STEMI differed significantly from our contemporaneous patients participating in a registry, with "real-world" patients being overall more morbid. Thus more pragmatic trials are required to evaluate the generalizability of results from recent RCTs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|